Education
About Us
Working with TipRanks
Follow Us
I-MAB (IMAB)
NASDAQ:IMAB
IMAB Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IMAB Stock 12 Month Forecast
Average Price Target
$7.40
▲(79.18% Upside)
| Highest Price Target$9.00 | Average Price Target$7.40 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$9
Buy
117.92%
Upside
Initiated
10/03/25
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), I-MAB (NASDAQ: IMAB) and Cidara Therapeutics (NASDAQ: CDTX)We are initiating coverage of I-Mab Biopharma (IMAB) with an Outperform rating and $9 PT. We believe (CD137) agonist, givastomig, has a unique value proposition in 1L gastroesophageal adenocarcinomas (GEA) through its synergistic immune-amplifying activity. While 4-1BB is well clinically validated in its ability to enhance immune function, the target has been plagued by issues with toxicity. I- Mab’s three key design decisions—Fc-inert, tetravalent, tumor- associated antigen conditional—look to be the optimal format for activating 4-1BB, in our view. Giva has a clean safety profile with modest single-agent activity.
BTIG
$7
Buy
69.49%
Upside
Initiated
10/01/25
H.C. Wainwright
$7
Buy
69.49%
Upside
Reiterated
09/17/25
Needham
$6
Buy
45.28%
Upside
Reiterated
09/08/25
I-Mab's Strategic Expansion and Financial Stability Justify Buy Rating Amid Promising Clinical DevelopmentsWe think I-Mab's decision to double down on giva makes sense, given the company's strong cash position after a recent financing (runway through 4Q:28) and encouraging initial dose escalation results reported for giva earlier this year (note). We maintain our Price Target. A randomized Phase II vs. nivo + chemo is expected to commence early next year following the 1L GC expansion cohort update. Topline PFS data are guided for 2027. Two additional ISTs will evaluate giva + nivo + chemo in the neoadjuvant setting. Disclaimers GIL BLUM, PH.D.
Brookline Capital Markets
$6→$8
Buy
93.70%
Upside
Reiterated
08/28/25
Lucid Capital
$5
Buy
21.07%
Upside
Initiated
05/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$9
Buy
117.92%
Upside
Initiated
10/03/25
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), I-MAB (NASDAQ: IMAB) and Cidara Therapeutics (NASDAQ: CDTX)We are initiating coverage of I-Mab Biopharma (IMAB) with an Outperform rating and $9 PT. We believe (CD137) agonist, givastomig, has a unique value proposition in 1L gastroesophageal adenocarcinomas (GEA) through its synergistic immune-amplifying activity. While 4-1BB is well clinically validated in its ability to enhance immune function, the target has been plagued by issues with toxicity. I- Mab’s three key design decisions—Fc-inert, tetravalent, tumor- associated antigen conditional—look to be the optimal format for activating 4-1BB, in our view. Giva has a clean safety profile with modest single-agent activity.
BTIG
$7
Buy
69.49%
Upside
Initiated
10/01/25
H.C. Wainwright
$7
Buy
69.49%
Upside
Reiterated
09/17/25
Needham
$6
Buy
45.28%
Upside
Reiterated
09/08/25
I-Mab's Strategic Expansion and Financial Stability Justify Buy Rating Amid Promising Clinical DevelopmentsWe think I-Mab's decision to double down on giva makes sense, given the company's strong cash position after a recent financing (runway through 4Q:28) and encouraging initial dose escalation results reported for giva earlier this year (note). We maintain our Price Target. A randomized Phase II vs. nivo + chemo is expected to commence early next year following the 1L GC expansion cohort update. Topline PFS data are guided for 2027. Two additional ISTs will evaluate giva + nivo + chemo in the neoadjuvant setting. Disclaimers GIL BLUM, PH.D.
Brookline Capital Markets
$6→$8
Buy
93.70%
Upside
Reiterated
08/28/25
Lucid Capital
$5
Buy
21.07%
Upside
Initiated
05/28/25
Best Analysts Covering I-MAB
1 Month
xxx
Success Rate
3/5 ratings generated profit
Average Return
+39.58%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +39.58% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+110.28%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +110.28% per trade.
1 Year
Success Rate
4/5 ratings generated profit
Average Return
+85.88%
reiterated a buy rating 17 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +85.88% per trade.
2 Years
xxx
Success Rate
4/5 ratings generated profit
Average Return
+85.88%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +85.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IMAB Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
8
8
6
5
4
Buy
0
0
2
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
8
8
8
7
Each month's total comprises the sum of three months' worth of ratings.
IMAB Financial Forecast
IMAB Stock Forecast FAQ
What is IMAB’s average 12-month price target, according to analysts?
Based on analyst ratings, I-MAB’s 12-month average price target is 7.40.
What is IMAB’s upside potential, based on the analysts’ average price target?
I-MAB has 79.18% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IMAB a Buy, Sell or Hold?
I-MAB has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is I-MAB’s price target?
The average price target for I-MAB is 7.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $6.00. The average price target represents 79.18% Increase from the current price of $4.13.
The highest analyst price target is $9.00 ,the lowest forecast is $6.00. The average price target represents 79.18% Increase from the current price of $4.13.
What do analysts say about I-MAB?
I-MAB’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of IMAB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.